NCR Online Journal

Radiation-induced Esophagitis Market Size and Share Analysis, Leading Companies, Emerging Drugs, and Epidemiology Forecast

 Breaking News
  • No posts were found

Radiation-induced Esophagitis Market Size and Share Analysis, Leading Companies, Emerging Drugs, and Epidemiology Forecast

May 13
05:35 2021
Radiation-induced Esophagitis Market Size and Share Analysis, Leading Companies, Emerging Drugs, and Epidemiology Forecast

Delveinsight Business Research LLP

DelveInsight’s “Radiation-induced Esophagitis Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Radiation-induced Esophagitis, historical and forecasted epidemiology as well as the Radiation-induced Esophagitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Radiation-induced esophagitis is the frequent and dose-limiting toxicity of thoracic radiotherapy (RT), especially when delivered concurrently with cytotoxic chemotherapy. Radiation esophagitis is inflammation, edema, erythema, and erosion of the mucosal surface of the esophagus caused by radiation therapy to nearby or related structures that cause cell damage, produce proinflammatory cytokines and lead to the development of free-oxygen radical species related to radiation therapy.

RT esophagitis can be classified as acute or late. The time frame of acute side effects is generally taken to mean ≤3 months after completion of treatment, although RT esophagitis most commonly onsets 2–3 weeks after the initiation of RT, lasting up to 4 weeks after RT completion. By definition, “late” refers to >3 months after the completion of RT; the median time of onset of late esophageal injury is 6 months, with some instances diagnosed at 1 year or later.

Get FREE sample copy at:

The Radiation-induced Esophagitis market report also covers emerging drugs, current treatment practices, Radiation-induced Esophagitis market share of the individual therapies, current and forecasted Radiation-induced Esophagitis Market Size from 2017 to 2030 segmented by seven major markets. 

The report provides a detailed current Radiation-induced Esophagitis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market. 

Radiation-induced Esophagitis Market

Radiation-induced Esophagitis Market Key Facts

  • According to a study published by Hawkins et al., locally advanced non–small cell lung cancer (NSCLC) is often treated with concurrent chemotherapy and radiation. Radiation esophagitis (RE) is a common complication of this treatment, with the incidence of grade 3 or greater symptoms having been reported to be as high as 25% in prospective trials.

  • As per the study by Murro et al., the esophagus is frequently exposed to radiation during the treatment of advanced stages of common cancers such as lung, breast, and esophagus. However, symptomatic radiation esophagitis requiring endoscopic and histologic evaluation occurs quite rarely, affecting less than 1% of patients receiving radiation treatment.

  • Radiation esophagitis is extremely rare and affects only 1% of patients undergoing mediastinal radiation for chest and thoracic cancers were concluded in the study published by Jakate et al.

Key Benefits of Radiation-induced Esophagitis Market Report

  • Radiation-induced Esophagitis market report provides an in-depth analysis of Radiation-induced Esophagitis Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major markets, i.e. EU5 (Germany, Italy, Spain, France, and the UK), Japan, and the United States.

  • The Radiation-induced Esophagitis market report will help in developing business strategies by understanding the Radiation-induced Esophagitis Market trends & developments, key players, and future market competition that will shape and drive the Radiation-induced Esophagitis market in the upcoming years.

  • The Radiation-induced Esophagitis market report covers Radiation-induced Esophagitis current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.

  • The report provides a detailed assessment of the Radiation-induced Esophagitis market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population,  comparative analysis of pipeline products with detailed clinical profiles, and other factors. 

Radiation-induced Esophagitis Market

Radiation-induced Esophagitis market size shall increase significantly during the forecast period owing to the launch of upcoming therapies. Extensive research and development, and rising awareness and incident will also fuel the growth of the Radiation-Induced Esophagitis market

The Radiation-induced Esophagitis market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Radiation-induced Esophagitis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology. 

The report gives a thorough detail of the Radiation-induced Esophagitis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders. 

Radiation-induced Esophagitis Epidemiology

The Radiation-induced Esophagitis epidemiology section covers insights about the historical and current Radiation-induced Esophagitis patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Radiation-induced Esophagitis Epidemiology Segmentation –

  • Total Incident cases of major cancers (lung, breast, etc.)

  • Total Incident cases of Radiation-Induced Esophagitis in major cancers (lung, breast, etc.)

  • Grade-specific Incident cases

  • Type-specific Incident cases

  • Diagnosed and Treatable cases

Radiation-induced Esophagitis Drugs Uptake and Key Market Players

The Radiation-induced Esophagitis Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Radiation-induced Esophagitis market or expected to get launched in the market during the study period. The analysis covers Radiation-induced Esophagitis market uptake by drugs; patient uptake by therapies; and sales of each drug.    

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The emerging drug landscape does not represent a particularly promising picture due to the lack of later-stage clinical products which is quite evident based on the scarcity of clinical trials being conducted for the pivotal stage in 7MM.

At present, Galera Therapeutics is developing GC4419 which is a highly selective small molecule superoxide dismutase (SOD) mimetic designed to protect normal tissues from radiation-induced damages. The company is conducting a Phase IIa clinical study to evaluate the efficacy of GC4419 in lowering the incidence of radiation-induced esophagitis among lung cancer patients.

The increase in research and development activities, the rise in demand for effective therapies among patients, and the emergence of better diagnostic tools for the disease are projected to fuel the growth of the Radiation-Induced Esophagitis market. The market is currently devoid of any approved therapies; therefore, the launch of the upcoming therapies will also make a positive impact on the market, thereby driving its growth during the forecast period.

Table of Content

1. Key Insights

2. Executive Summary 

3. Radiation-induced Esophagitis Competitive Intelligence Analysis

4. Radiation-induced Esophagitis Market Overview at a Glance

5. Radiation-induced Esophagitis Disease Background and Overview

6. Radiation-induced Esophagitis Patient Journey

7. Radiation-induced Esophagitis Epidemiology and Patient Population

8. Radiation-induced Esophagitis Treatment Algorithm, Current Treatment, and Medical Practices

9. Radiation-induced Esophagitis Unmet Needs

10. Key Endpoints of Radiation-induced Esophagitis Treatment

11. Radiation-induced Esophagitis Marketed Products

12. Radiation-induced Esophagitis Emerging Therapies

13. Radiation-induced Esophagitis Seven Major Market Analysis

14. Attribute Analysis

15. Radiation-induced Esophagitis Market Outlook (7 major markets)

16. Radiation-induced Esophagitis Access and Reimbursement Overview

17. KOL Views on the Radiation-induced Esophagitis Market.

18. Radiation-induced Esophagitis Market Drivers

19. Radiation-induced Esophagitis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Get FREE sample copy at:

Latest Report By DelveInsight – 

Hypertrophic Cardiomyopathy Market
DelveInsight’ s “Hypertrophic Cardiomyopathy Market Insights, Epidemiology and Market Forecast – 2030” report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology and the Hypertrophic Cardiomyopathy market size, share, trends, and forecast for the seven major markets (i.e. the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. 

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States